WVE Wave Life Sciences Ltd.

NASDAQ
$5.41

Wave Life Sciences Ltd. (WVE) is expected to report earnings on October 29, 2026, before the market open. The consensus earnings estimate is a loss of $0.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.7% since its last earnings release on July 30, 2026.

Wave Life Sciences Missed Consensus Estimates
Thursday, July 30, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 7:30 AM ET
Earnings Whisper
-
vs ($0.33)
Rev est $8.57M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.55

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Wave Life Sciences Ltd.

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow